Ultragenyx Pharmaceutical
RARE
206 hedge funds and large institutions have $5.2B invested in Ultragenyx Pharmaceutical in 2020 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 82 increasing their positions, 66 reducing their positions, and 22 closing their positions.
102% more call options, than puts
Call options by funds: $5.91M | Put options by funds: $2.92M
68% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 22
24% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 66
8% more funds holding
Funds holding: 191 → 206 (+15)
5% more capital invested
Capital invested by funds: $4.94B → $5.2B (+$256M)
1.44% less ownership
Funds ownership: 105.8% → 104.36% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$56.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$20M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.6M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$9.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$40.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.5M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$19.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.2M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$13.6M |
RARE Hedge Fund Activity: Q3 2020 in Review
206 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2020, worth a combined $5.2B — up 5.2% from $4.94B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new RARE positions and 22 closed out — a net gain of 15 holders — while 82 added to existing stakes and 66 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $56.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $40.6M sold.
- 206 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2020, up from 191 in Q2 2020.
- Funds reported $5.2B of Ultragenyx Pharmaceutical stock for Q3 2020, up 5.2% quarter-over-quarter.
- 37 funds opened new Ultragenyx Pharmaceutical positions in Q3 2020 and 22 closed out, a net change of +15 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2020 was T. Rowe Price Associates, an estimated $56.5M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2020 was EcoR1 Capital, an estimated $40.6M sold.
Based on aggregated 13F filings for Q3 2020.